ResMed Management
Management criteria checks 4/4
ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 12.42 years. total yearly compensation is $14.12M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $134.29M. The average tenure of the management team and the board of directors is 7.6 years and 7.3 years respectively.
Key information
Mick Farrell
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | 8.28% |
| CEO tenure | 12.4yrs |
| CEO ownership | 0.3% |
| Management average tenure | 7.6yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Jul 29
Shareholders Would Enjoy A Repeat Of ResMed's (NYSE:RMD) Recent Growth In Returns
Jun 23Do ResMed's (NYSE:RMD) Earnings Warrant Your Attention?
Jun 11ResMed: A Sleeping Giant Hiding In Plain Sight
Jun 09There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price
May 30ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly
May 18ResMed: Cornering The Market In Sleep Solutions
Apr 24ResMed Inc. (NYSE:RMD) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 15If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
Feb 26ResMed Inc.'s (NYSE:RMD) Share Price Not Quite Adding Up
Feb 14Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Feb 10ResMed: Snoozers Can Be Winners
Feb 01ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Jan 24ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price
Jan 13ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency
Jan 01ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03Why ResMed Is One Of My Top Picks In 2024
Jan 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | n/a | n/a | US$1b |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | US$14m | US$1m | US$1b |
| Mar 31 2024 | n/a | n/a | US$958m |
| Dec 31 2023 | n/a | n/a | US$890m |
| Sep 30 2023 | n/a | n/a | US$907m |
| Jun 30 2023 | US$14m | US$1m | US$898m |
| Mar 31 2023 | n/a | n/a | US$863m |
| Dec 31 2022 | n/a | n/a | US$809m |
| Sep 30 2022 | n/a | n/a | US$786m |
| Jun 30 2022 | US$12m | US$1m | US$779m |
| Mar 31 2022 | n/a | n/a | US$779m |
| Dec 31 2021 | n/a | n/a | US$522m |
| Sep 30 2021 | n/a | n/a | US$500m |
| Jun 30 2021 | US$10m | US$1m | US$475m |
| Mar 31 2021 | n/a | n/a | US$457m |
| Dec 31 2020 | n/a | n/a | US$699m |
| Sep 30 2020 | n/a | n/a | US$680m |
| Jun 30 2020 | US$10m | US$1m | US$622m |
| Mar 31 2020 | n/a | n/a | US$513m |
| Dec 31 2019 | n/a | n/a | US$455m |
| Sep 30 2019 | n/a | n/a | US$419m |
| Jun 30 2019 | US$10m | US$967k | US$405m |
Compensation vs Market: Mick's total compensation ($USD14.12M) is about average for companies of similar size in the US market ($USD13.58M).
Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.
CEO
Mick Farrell (53 yo)
Mr. Michael J. Farrell, also known as Mick, is Lead Independent Director of Zimmer Biomet Holdings, Inc. from May 29, 2025. Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 12.4yrs | US$14.12m | 0.32% $ 134.3m | |
| Founder | no data | US$719.69k | 0.046% $ 19.4m | |
| Chief Financial Officer | 19.6yrs | US$3.23m | 0.061% $ 25.4m | |
| Chief Legal Officer & Secretary | 2.1yrs | US$2.15m | 0.0078% $ 3.3m | |
| Chief Product Officer | 9.3yrs | US$3.60m | 0.019% $ 7.8m | |
| Chief Information Officer | 1.5yrs | no data | no data | |
| Chief Investor Relations Officer | less than a year | no data | no data | |
| Chief Compliance Officer | 7.6yrs | no data | no data | |
| Chief Marketing Officer | 1.8yrs | no data | no data | |
| Chief People Officer | 4.4yrs | no data | no data | |
| Chief Strategy Officer | 10.7yrs | no data | no data | |
| Chief Medical Officer | 8.6yrs | no data | no data |
Experienced Management: RMD's management team is seasoned and experienced (7.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 12.4yrs | US$14.12m | 0.32% $ 134.3m | |
| Founder | 36.2yrs | US$719.69k | 0.046% $ 19.4m | |
| Independent Director | 20yrs | US$348.72k | 0.011% $ 4.8m | |
| Lead Independent Director | 20.6yrs | US$381.22k | 0.015% $ 6.5m | |
| Independent Non-Executive Director | 6.3yrs | US$329.97k | 0.0032% $ 1.4m | |
| Independent Director | 6.8yrs | US$329.97k | 0.0060% $ 2.5m | |
| Independent Director | 11.8yrs | US$369.97k | 0.011% $ 4.8m | |
| Independent Director | 7.8yrs | US$334.97k | 0.0058% $ 2.4m | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 3.8yrs | US$329.97k | 0.0026% $ 1.1m | |
| Independent Director | 3.8yrs | US$329.97k | 0.0020% $ 845.3k | |
| Independent Director | no data | no data | no data |
Experienced Board: RMD's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/26 07:37 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 56 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| Michael Polark | Baird |
| David Rescott | Baird |